Robert Driscoll
Stock Analyst at Wedbush
(1.97)
# 3,123
Out of 4,981 analysts
148
Total ratings
30.77%
Success rate
-4.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Outperform | $73 → $77 | $46.55 | +65.41% | 6 | Sep 11, 2025 | |
| REPL Replimune Group | Downgrades: Neutral | $19 → $4 | $5.73 | -30.19% | 6 | Jul 22, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $12.59 | +114.46% | 1 | Jul 14, 2025 | |
| KURA Kura Oncology | Reiterates: Outperform | $36 | $8.19 | +339.56% | 10 | Jun 20, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.49 | +168.46% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $1.43 | +319.58% | 3 | May 9, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $4.81 | +253.43% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $7.74 | +55.04% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $7.12 | +349.44% | 6 | Feb 26, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $24.63 | +111.12% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $12.54 | +123.29% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $3.25 | +392.31% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $11.52 | +160.42% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $9.50 | +436.84% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.81 | +517.13% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $6.53 | +451.30% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.54 | +612.44% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $5.19 | +150.48% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $6.53 | +99.08% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $24.05 | +207.69% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $3.57 | +124.09% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.27 | +451.18% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $2.00 | +300.00% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.46 | -10.31% | 4 | May 19, 2020 |
Revolution Medicines
Sep 11, 2025
Maintains: Outperform
Price Target: $73 → $77
Current: $46.55
Upside: +65.41%
Replimune Group
Jul 22, 2025
Downgrades: Neutral
Price Target: $19 → $4
Current: $5.73
Upside: -30.19%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $12.59
Upside: +114.46%
Kura Oncology
Jun 20, 2025
Reiterates: Outperform
Price Target: $36
Current: $8.19
Upside: +339.56%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.49
Upside: +168.46%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $1.43
Upside: +319.58%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $4.81
Upside: +253.43%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $7.74
Upside: +55.04%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $7.12
Upside: +349.44%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $24.63
Upside: +111.12%
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $12.54
Upside: +123.29%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $3.25
Upside: +392.31%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $11.52
Upside: +160.42%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $9.50
Upside: +436.84%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.81
Upside: +517.13%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $6.53
Upside: +451.30%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.54
Upside: +612.44%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.19
Upside: +150.48%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $6.53
Upside: +99.08%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $24.05
Upside: +207.69%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $3.57
Upside: +124.09%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.27
Upside: +451.18%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $2.00
Upside: +300.00%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.46
Upside: -10.31%